REC Ref	IRAS No.	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited
16/EM/0259	165592	HRA Approval	A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus masitinib alone, versus Best Supportive Care, in third or fourth line treatment of patients with metastatic colorectal cancer			Yes	10/06/2017	0	0	0	39	32	71
17/WS/0300	191416	HRA Approval	A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma			Yes	17/07/2017	0	0	0	10	45	55
16/NW/0379	200426	HRA Approval	Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer			Yes	26/02/2017	0	0	0	0	23	23
16/WM/0036	180476	HRA Approval	Accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and its potential to reduce antibiotic usage in mothers with risk factors			No		0	0	0	122		
16/SC/0390	190073	HRA Approval	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing forms of multiple sclerosis			No		0	0	0	0		
17/LO/0100	200545	HRA Approval	A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens			No		0	0	0	201		
17/EM/0005	215706	HRA Approval	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction			No		0	0	0	101		
17/EE/0330	213102	HRA Approval	A Prospective, Non-randomized, Consecutive Series, Multicentre, Observational Study to Evaluate the Clinical Outcome of Ceramic-on-Ceramic Hip Resurfacing Arthroplasty Using the H1 hip joint ceramic non-porous non-cemented prosthesis			No		0	0	0			
17HH0797	220423	HRA Approval	A multi-center, non-randomized study to evaluate the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction.			No		0	0	0			
16/LO/2038	208640	HRA Approval	A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)			No		0	0	0			
16/LO/1024	195085	HRA Approval	Safety and efficacy of Belimumab After B cell depleTion therapy in systemic LUPUS erythematosus ?BEAT LUPUS			No		0	0	0			
16/LO/1258	171996	HRA Approval	Randomised Clinical Trial of Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease			No		0	0	0	35		
17/SC/0411	217819	HRA Approval	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100X (DNA PLASMID VECTORS EXPRESSING HPV-16 E6/E7, HPV-18 E6/E7) DELIVERED intramuscularly FOLLOWED BY EP WITH CELLECTRA? 5PSP FOR THE TREATMENT OF HISTOLOGICALLY PROVEN CIN2 OR CIN3 ASSOCIATED WITH HPV-16 AND/OR HPV-18			No		0	0	0			

16/LO/2126	218039	HRA Approval	A randomized trial comparing the ELUVIA? drug-eluting stent versus bare Metal self-expanding nitINol stEnts in the treatmeNt of superficial femoral and/or proximal popliteal arTeries			No		0	0	0	190		
16/SC/0066	194868	HRA Approval	Open-label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in a previous dupilumab asthma clinical study			Yes	16/10/2017	0	0	0	197	13	210
16/LO/1700	208204	HRA Approval	A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis			Yes	08/02/2017	0	0	0	0	26	26
17/LO/0052	212454	HRA Approval	Evaluation of Uterine Patency following Sonography-guided Transcervical Ablation of Fibroids			Yes	03/04/2017	0	0	0	57	18	75
17/LO/0082	217324	HRA Approval	A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery			Yes	02/10/2017	0	0	0	194	6	200
16/NW/0628	194200	HRA Approval	A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of DS-1040B in subjects with acute ischemic stroke.			No		0	0	0			
16/LO/1494	208340	HRA Approval	A Phase III, Randomised, Multicentre, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects			Yes	20/03/2017	0	0	0	9	31	40
16/LO/1984	215378	HRA Approval	A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK- 3682 + MK-8408 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection			Yes	20/02/2017	0	0	0	8	17	25
16/LO/1891	213918	HRA Approval	A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH)			Yes	05/07/2017	0	0	0	11	110	121
16/SC/0601	209260	HRA Approval	A long term Extension study to evaluate the safety of Filgotinib in Subjects with Ulcerative Colitis			No		0	0	0	40		
16/SC/0600	209261	HRA Approval	Combined Phase 2b/3, Double blind, Randomised, Placebo- Controlled Studies Evaluating the Efficacy and safety of Filgotinib in the Indiction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease			No		0	0	0	13		
16/SC/0630	209259	HRA Approval	Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn?s Disease			No		0	0	0	29		
16/SC/0631	209258	HRA Approval	A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn?s Disease GS-US-419-3896			No		0	0	0	0		
16/NE/0415	217915	HRA Approval	A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir (ODV), with or without Simeprevir (SMV), in Treatment-Na?ve Subjects with Genotype 1, 2 or 3 Chronic Hepatitis C infection with or without compensated Child Pugh A Cirrhosis			No		0	0	0	35		
16/LO/1979	193891	HRA Approval	A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer			No		0	0	0	9		

17/LO/0024	212247	HRA Approval	An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination with Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma			No		0	0	0			
16/NE/0067	199159	HRA Approval	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients with Parkinson?s Disease.			Yes	23/08/2017	0	0	0	39	44	83
17/LO/0705	214843	HRA Approval	TRIAL ON RADICAL UPFRONT SURGERY IN ADVANCED OVARIAN CANCER AMENDMENT FOR GERMANY WITH EXTENDED PART FOR FRAGILITY AND LONG TERM QUALITY OF LIFE			Yes	04/09/2017	0	0	0	60	34	94
16/EM/0436	213166	HRA Approval	SINGLE ARM, STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAIVE ADULT AND ADOLESCENT PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)			No		0	0	0	23		
16/LO/2148	219354	HRA Approval	A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate-Risk Prostate Cancer that is Associated with an MRI Lesion			Yes	21/06/2017	0	0	0	56	75	131
17/NW/0036	220218	HRA Approval	A Phase II, multi-centre Study of BGB324 in combination with Pembrolizumab in Patients with Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)			No		0	0	0	5		
17/LO/0113	219400	HRA Approval	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease			No		0	0	0	240		
16/WS/0197	186191	HRA Approval	An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer			No		0	0	0	129		
16/NE/0238	204031	HRA Approval	The British Heart Foundation older patients with non-ST SEgmeNt elevatIOn myocaRdial infarction Randomized Interventional TreAtment Trial			Yes	22/09/2017	0	0	0	201	32	233
17/EE/0080	220727	HRA Approval	A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen			No		0	0	0	29		
16/NS/0094	206213	HRA Approval	BioImpedance Spectroscopy to Maintain Renal Output: The BISTRO Trial			No		0	0	0	65		
17/EE/0081	219405	HRA Approval	An open label, single arm pilot study of OncoSil?, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies.			No		0	0	0	62		
17/NW/0175	222859	HRA Approval	A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult patients with Persistent/Chronic Immune Thrombocytopenia			Yes	28/06/2017	0	0	0	58	6	64
17/LO/0418	220385	HRA Approval	A Phase II Multi Centre Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung			No		0	0	0			
16/EM/0465	214926	HRA Approval	A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations			No		0	0	0			
17/NW/0180	220257	HRA Approval	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy.			No		0	0	0	148		

16/EM/0220	199415	HRA Approval	A randomized parallel group phase III trial of OSE2101 as 2nd or 3rd line compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic (IV) Non-Small-Cell Lung Cancer. (OSE2101C301)			No		0	0	0			
17/SC/0142	215503	HRA Approval	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension.			Yes	08/10/2017	0	0	0	188	13	201
17/EM/0116	222773	HRA Approval	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson?s Disease Experiencing End of Dose ?Wearing-Off?			Yes	18/07/2017	0	0	0	0	47	47
17/LO/0783	225826	HRA Approval	A Multicenter, Parallel-Group, Randomized, Cross-Over Trial to Compare the Efficacy of LUMINITY? and SonoVue? in the Evaluation of Left Ventricular Endocardial Border Definition			No		0	0	0	40		
17/EM/0241	223736	HRA Approval	Safety and efficacy analysis of FRED/FRED Jr embolic device in aneurysm treatment			No		0	0	0	62		
16/EE/0463	214371	HRA Approval	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.			No		0	0	0	71		
17/SC/0253	226685	HRA Approval	A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adju-vant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer.			No		0	0	0			
17/NE/0149	224550	HRA Approval	(M16-298) randomized, double-blind, placebo-controlled phase 3 study of rovalpituzumab tesirine (Rova-T) as maintenance therapy following four cycles of firstline therapy with a platinum doublet in subjects with extensive stage disease (ED) SCLC			No		0	0	0			
16/WM/0448	212745	HRA Approval	A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir.			No		0	0	0			
17/ES/0051	223060	HRA Approval	CANC 33870: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer			No		0	0	0			
17/EE/0264	228153	HRA Approval	A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC) (POSEIDON)			No		0	0	0			
17/EE/0177	220722	HRA Approval	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).			Yes	03/10/2017	0	0	0	63	7	70
16/WA/0156	204506	HRA Approval	Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: a multicentre randomised controlled trial (UK Mini Mitral).			No		0	0	0			
17/SW/0127	225959	HRA Approval	A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate.			No		0	0	0			

17/NE/0174	224141	HRA Approval	A PERFORMANCE EVALUATION STUDY OF ARQUER?S MCM5 ELISA TEST TO AID IN THE MONITORING OF BLADDER CANCER RECURRENCE			Yes	06/09/2017	0	0	0	65	5	70
17/YH/0311	229294	HRA Approval	A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies			No		0	0	0			
17/SC/0394	229032	HRA Approval	An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib.			No		0	0	0			
17/LO/1149	220763	HRA Approval	A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients.			No		0	0	0			
17/LO/1320	229845	HRA Approval	Single-arm, phase II study of Luspatercept (ACE-536) in anemic patients with MPN-associated myelofibrosis.			No		0	0	0			
17/SC/0408	228262	HRA Approval	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease.			No		0	0	0			
17/LO/1429	223671	HRA Approval	A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL).			No		0	0	0			
16/LO/1812	211705	HRA Approval	Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF)			Yes	27/07/2017	0	0	0	120	50	170
17/LO/0089	219229	HRA Approval	A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disease			Yes	15/07/2017	0	0	0	21	29	50
16/SC/0552	213579	HRA Approval	A PROSPECTIVE INTERNATIONAL MULTICENTRE RANDOMISED CONTROLLED SINGLE BLIND CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHAEMIC STROKE MEDISINTERNATIONAL)			No		0	0	0			
17/LO/0304	222475	HRA Approval	A double-blind, randomised, placebo-controlled, parallel-group, phase 2, dose-ranging trial to evaluate the efficacy, safety and tolerability of oral Litoxetine 10mg, 20mg and 40mg twice daily (BID) versus placebo in women with mixed urinary continence			No		0	0	0	54		
16/EE/0421	209972	HRA Approval	A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension			No		0	0	0			
17/LO/0444	218822	HRA Approval	A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-ActingAntiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection			Yes	15/06/2017	0	0	0	1	6	7
16/WM/0285	202235	HRA Approval	A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mixed Dyslipidemia			Yes	01/08/2017	0	0	0	16	12	28
17/LO/0401	217921	HRA Approval	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies.			Yes	06/06/2017	0	0	0	22	13	35
17/LO/1003	206965	HRA Approval	Perforated Punctal Plug as an alternative to the three snip punctoplasty for the treatment of acquired lacrimal punctum stenosis			Yes	04/09/2017	0	0	0	0	24	24

16/WM/0514	213012	HRA Approval	The B-ADENOMA Study: Bowel Scope - Accuracy of Detection using ENdocuff Optimisation of Mucosal Abnormalities			No		0	0	0			
16/NW/0877	216860	HRA Approval	A Safety and Tolerability Study of LY3303560 in Alzheimer's Disease			Yes	06/10/2017	0	0	0	6	66	72
17/SC/0122	224090	HRA Approval	AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children			Yes	18/07/2017	0	0	0	63	6	69
16/SC/0338	191612	HRA Approval	Prospective Interruption of Therapy towards a Cure for HIV (PITCH) Pilot Study			No		0	0	0			
16/YH/0157	204585	HRA Approval	PLATO - PersonaLising Anal cancer radioTherapy dOse - Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5			No		0	0	0			
17/NE/0165	217768	HRA Approval	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS			No		0	0	0			
17/LO/0719	226571	HRA Approval	Assessment of viral shedding in children previously in receipt of multiple doses of live attenuated influenza vaccine (LAIV) compared to influenza vaccine-na?ve controls			Yes	16/10/2017	0	0	0	31	7	38
17/LO/1091	229631	HRA Approval	A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infection			No		0	0	0			
17/SC/0164	210735	HRA Approval	A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation			Yes	06/09/2017	0	0	0	84	6	90
17/EM/0301	209448	HRA Approval	Sedation and Weaning in Children			No		0	0	0			
17/EE/0097	186866	HRA Approval	A Phase I Open-Labelled Trial investigating immunisation strategies using Ad4, MVA and rpg140 combinations in order to maximise antibody responses			No		0	0	0	6		
16/LO/1169	198386	HRA Approval	Determining the effects of gut content on satiety			Yes	09/03/2017	0	0	0	3	3	6
16/LO/1452	198681	HRA Approval	Do statins increase sensitivity to glucagon?			Yes	07/04/2017	0	0	0	19	53	72
17/LO/0524	202816	HRA Approval	Catheter ABlation of LOw VOltage regions in the treatment of persistent Atrial Fibrillation (ABLOVO-AF study)			Yes	24/08/2017	0	0	0	18	80	98
17/LO/0047	204949	HRA Approval	Enhanced Personalised and Integrated Care for Infection Management at the Point of Care - EPIC IMPOC			Yes	08/05/2017	0	0	0	26	27	53
16/LO/2021	210536	HRA Approval	Effect of increased colonic propionate on weight loss during a hypo-caloric diet			Yes	21/02/2017	0	0	0	0	8	8
17/LO/0173	210195	HRA Approval	Clinical application and evaluation of advanced diagnostic tools in women with suspected endometrial cancer.			Yes	13/06/2017	0	0	0	120	12	132
16/LO/1584	195717	HRA Approval	Spectroscopy for blood perfusion monitoring			No		0	0	0	14		
17/LO/0037	217265	HRA Approval	A novel robotic system for trans-anal surgery			No		0	0	0	76		
17/LO/0465	218759	HRA Approval	ADJUNCTIVE GP ABLATION IN REDO-PVI STUDY (ADD-GP): PAROXYSMAL ATRIAL ARRHYTHMIAS AFTER PULMONARY VEIN ISOLATION ARE DRIVEN BY ECTOPY-TRIGGERING LEFT ATRIAL GANGLIONATED PLEXI			Yes	21/07/2017	0	0	0	54	37	91
16/NW/0895	211402	HRA Approval	Feasibility study of a physical activity intervention in breast cancer survivors			Yes	02/03/2017	0	0	0	1	48	49
17/WM/0124	219181	HRA Approval	Assessment of arterial stiffness in patients with end-stage kidney disease using shear-wave elastography			Yes	15/06/2017	0	0	0	42	2	44
17/EE/0147	218349	HRA Approval	In comparison to usual care alone, does an adjunctive pre-surgery dietetic service improve the post-surgical nutritional outcomes for patients with pancreatic cancer? A pilot study			No		0	0	0	1		
17/LO/0862	195365	HRA Approval	The effects of fruits and vegetables on vascular function in prehypertensive participants: a pilot study			Yes	13/09/2017	0	0	0	2	53	55
17/LO/1095	225278	HRA Approval	Investigation of the metabolic effects of duodenal resurfacing on insulin resistant women wIth polycystic ovarian syndrome			No		0	0	0			
17/HRA/0916	223009	HRA Approval	On-demand computerised decision making and syringe labelling in paediatric emergency prescribing: a workload and feasibility assessment.			Yes	10/05/2017	0	0	0	29	41	70

17/LO/0742	219709	HRA Approval	A randomised controlled comparison of effectiveness of facemask pre-oxygenation and Transanal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) in bariatric patients undergoing general anesthesia			No		0	0	0	3		
17/LO/1129	226325	HRA Approval	An adaptive orthosis for hand osteoarthritis; feasibility and prototype			Yes	04/10/2017	0	0	0	7	20	27
17/LO/1390	229748	HRA Approval	Distribution of targeted educational materials to families after they attend emergency or urgent care with a child under 5 years old in non-urgent situation, in order to reduce future repeat non-urgent attendances			No		0	0	0	35		

Benchmark Met	Date Study Initiated	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Reasons for Delay
No		31/03/2017	31/03/2017	12/09/2016	16/03/2017	09/05/2017	Please Select	17/05/2017									Y		
Yes		05/01/2017	23/05/2017	12/04/2017	18/05/2017	02/06/2017	Please Select	07/06/2017									Y		
Yes		25/07/2016	03/02/2017	16/08/2016	03/02/2017	03/02/2017	Please Select	06/02/2017				Y							
No		10/06/2016	09/05/2017	23/08/2016	06/09/2017	08/09/2017	Please Select...					Y				Y			
No		15/07/2016	10/01/2017	13/10/2016	15/07/2016	10/01/2017	Please Select	26/01/2017							Y		Y		
No		09/08/2016	15/02/2017	24/04/2017	15/08/2017	04/09/2017	Please Select...		Y										
No		29/09/2016	24/02/2017	15/02/2017	24/05/2017	05/06/2017	Please Select	09/06/2017								Y			
No		17/09/2017	17/09/2017				Please Select	17/09/2017											
No		28/11/2016	27/04/2017	01/08/2017			Please Select...			Y									
No		20/07/2016	04/01/2017	23/01/2017			Please Select...			Y									
No		24/11/2016	20/03/2017	11/10/2016			Please Select...						Y			Y			
No		20/01/2017	20/03/2017	15/03/2017	20/01/2017	24/04/2017	Please Select...					Y							
No		01/06/2016	23/08/2017				Please Select...												

No		14/12/2016	06/03/2017	24/02/2017	12/09/2017	12/09/2017	Please Select	13/09/2017				Y				Y			
No		08/01/2016	20/03/2017	29/04/2016	08/01/2016	03/10/2017	Please Select	04/10/2017				Y				Y			
Yes		11/07/2016	13/01/2017	09/01/2017	15/12/2016	13/01/2017	Please Select	08/02/2017											
No		22/08/2016	18/01/2017	14/02/2017	18/01/2017	16/03/2017	Please Select	22/03/2017				Y							
No		21/12/2016	16/03/2017	15/03/2017	11/09/2017	26/09/2017	Please Select	27/09/2017				Y							
Site Not Confirmed		06/10/2016	23/03/2017	26/10/2016	04/10/2016		Site declined to participate				Y							Y	
Yes		13/10/2016	08/02/2017	02/11/2016	13/10/2016	17/02/2017	Please Select	17/02/2017											
Yes		10/11/2016	26/01/2017	26/01/2017	10/11/2016	03/02/2017	Please Select	10/02/2017											
No		15/11/2016	06/03/2017	09/01/2017	15/11/2016	17/03/2017	Please Select	24/03/2017						Y					
No		23/11/2016	01/03/2017	21/12/2016	24/11/2016	10/04/2017	Please Select	04/04/2017				Y		Y					
No		24/11/2016	28/03/2017	21/12/2016	24/11/2016	10/04/2017	Please Select	25/05/2017	Y						Y				
No		24/11/2016	01/03/2017	02/02/2017	24/11/2016	30/03/2017	Please Select	04/04/2017							Y				
No		25/11/2016	30/03/2017	17/01/2017	25/11/2016	30/03/2017	Please Select	04/04/2017						Y	Y			Y	
Site Not Confirmed		16/12/2016	01/06/2017	28/02/2017	16/12/2016	06/07/2017	Sponsor declined site confirmation			Y		Y							
No		04/01/2017	30/08/2017	20/12/2016	06/09/2017	08/09/2017	Please Select	08/09/2017											

No		10/01/2017	11/01/2017	05/04/2017			Please Select...					Y				Y			
No		08/05/2017	01/06/2017	01/06/2017	08/05/2017	10/07/2017	Please Select	11/07/2017						Y	Y		Y		
No		02/06/2017	02/06/2017	28/07/2017	27/07/2017	01/08/2017	Please Select	03/08/2017							Y	Y			
No		16/08/2017	16/08/2017	07/12/2016	16/08/2017	08/09/2017	Please Select	15/09/2017											
No		23/01/2017	10/02/2017	14/02/2017	07/04/2017	07/04/2017	Please Select	07/04/2017				Y				Y			
No		04/09/2017	03/09/2017	11/05/2017	14/08/2017	08/09/2017	Please Select...												
No		03/11/2016	31/01/2017	23/05/2017	15/09/2017	28/09/2017	Please Select	29/09/2017				Y				Y			
No		01/02/2017	30/05/2017	01/02/2017	02/08/2017	06/10/2017	Please Select	12/10/2017								Y			
No		01/02/2017	01/02/2017	08/08/2016	01/08/2017	21/08/2017	Please Select	22/08/2017								Y			
No		30/03/2017	20/06/2017	09/06/2017	08/05/2017	19/07/2017	Please Select	04/08/2017									Y		
No		23/02/2017	07/08/2017	04/10/2016	23/02/2017	11/10/2017	Please Select	12/10/2017											
No		26/02/2017	05/05/2017	08/05/2017	29/06/2017	06/07/2017	Please Select	06/07/2017	Y								Y		
Yes		20/10/2016	25/04/2017	19/05/2017	16/06/2017	22/06/2017	Please Select	23/06/2017											
Site Not Confirmed		03/02/2017	13/03/2017	12/06/2017	03/08/2017		Site declined to participate				Y		Y			Y			
No		14/03/2017	20/04/2017	19/01/2017	29/06/2017		Please Select...					Y				Y			
No		15/03/2017	15/03/2017	04/04/2017	02/08/2017	10/08/2017	Please Select	14/08/2017								Y	Y		

No		15/12/2016	17/03/2017	24/08/2016			Please Select...			Y								
No		21/03/2017	21/03/2017	24/04/2017	18/08/2017	25/09/2017	Please Select	25/09/2017					Y					
Yes		27/03/2017	01/06/2017	22/03/2017	27/03/2016	01/06/2017	Please Select	11/07/2017										
No		06/04/2017	24/08/2017	24/08/2017	25/09/2017	03/10/2017	Please Select...											
No		05/07/2017	19/07/2017	08/08/2017	18/09/2017	19/09/2017	Please Select	19/09/2017								Y		
No		12/06/2017	13/07/2017	30/01/2017	18/09/2017	22/09/2017	Please Select	04/10/2017	Y							Y		
No		30/05/2017	31/05/2017				Please Select...					Y						
No		10/05/2017	20/06/2017	19/06/2017	06/09/2017		Please Select...		Y							Y		
No		05/04/2017	05/04/2017	08/02/2017			Please Select...					Y						
No		07/06/2017	06/07/2017	05/07/2017			Please Select...					Y				Y		
No		02/06/2017	13/09/2017	12/09/2017			Please Select...											
Yes		31/05/2017	25/07/2017	24/07/2017	18/09/2017	26/09/2017	Please Select	27/09/2017										
No		14/06/2017	26/07/2017	19/06/2016			Please Select...											
No		19/06/2017	19/06/2017	03/07/2017			Please Select...										Y	

Yes		27/06/2017	28/06/2017	13/06/2017	08/08/2017	01/09/2017	Please Select	01/09/2017											
No		29/08/2017	06/09/2017				Please Select...												
No		07/08/2017	14/08/2017				Please Select...												
No		26/07/2017	26/07/2017	12/09/2017	09/10/2017		Please Select...												
No		10/08/2017	10/08/2017				Please Select...												
No		18/09/2017	18/09/2017	19/09/2017			Please Select...												
No		06/09/2017	06/09/2017				Please Select...												
No		12/01/2017	07/02/2017	28/11/2016	12/01/2017	07/06/2017	Please Select	28/06/2017				Y				Y			
Yes		27/01/2017	26/05/2017	27/03/2017	27/01/2017	16/06/2017	Please Select	16/06/2017											
No		16/02/2017	22/08/2017	10/01/2017	16/02/2017		Please Select...												
No		08/03/2017	31/03/2017	06/04/2017	16/05/2017	24/05/2017	Please Select	23/05/2017	Y				Y						
No		15/02/2017	25/04/2017	13/01/2017			Please Select...									Y			
Yes		08/03/2017	08/06/2017	05/05/2017	08/03/2017	09/06/2017	Please Select	09/06/2017											
Yes		17/03/2017	04/07/2017	22/06/2017	17/03/2017	20/07/2017	Please Select	05/07/2017											
Yes		02/05/2017	02/05/2017	23/03/2017	21/03/2017	24/05/2017	Please Select	31/05/2017											
Yes		22/03/2017	11/08/2017	01/08/2017	11/08/2017	11/08/2017	Please Select	23/08/2017											

Site Not Confirmed		30/03/2017	06/04/2017	06/04/2017	30/03/2017		Sponsor declined site confirmation			Y								
No		19/04/2017	26/07/2017	05/04/2017	19/04/2017	01/08/2017	Please Select	01/09/2017				Y						
Yes		07/02/2017	10/05/2017	18/04/2017	12/07/2017	12/07/2017	Please Select	14/07/2017										
No		09/05/2017	09/08/2017	22/11/2016	17/10/2017		Please Select...											
No		26/08/2016	06/09/2017	20/07/2016			Please Select...											
No		22/05/2017	20/06/2017	07/09/2017	22/05/2017		Please Select...				Y				Y			
Yes		20/06/2017	08/09/2017	20/06/2017	04/10/2017	09/10/2017	Please Select	16/10/2017										
Site Not Confirmed		03/07/2017	24/08/2017	24/08/2017			Sponsor declined site confirmation											
No		08/06/2017	08/06/2017	26/05/2017	23/08/2017	31/08/2017	Please Select	31/08/2017					Y					
No		13/07/2017	01/09/2017				Please Select...											
No		16/01/2017	07/09/2017	07/09/2017	16/01/2017	13/09/2017	Please Select	06/10/2017										
Yes		03/03/2017	03/03/2017	28/10/2016	03/03/2017	06/03/2017	Please Select	06/03/2017										
No		17/01/2017	25/01/2017	19/01/2017	17/01/2017	13/02/2017	Please Select	21/02/2017				Y						
No		07/03/2017	18/05/2017	18/05/2017	07/03/2017	05/06/2017	Please Select	05/06/2017		Y								
Yes		16/03/2017	16/03/2017	21/02/2017	23/03/2017	11/04/2017	Please Select	11/04/2017										
Yes		23/01/2017	13/02/2017	13/02/2017	23/01/2017	13/02/2017	Please Select	13/02/2017										
No		12/12/2017	01/02/2017	04/05/2017	01/06/2017	01/06/2017	Please Select	01/06/2017	Y									
No		01/07/2016	10/01/2017	20/01/2017	24/01/2017	24/01/2017	Please Select	02/06/2017						Y	Y			
No		01/12/2016	30/03/2017	06/06/2017	14/06/2017	14/06/2017	Please Select	14/06/2017	Y									
No		24/02/2017	21/04/2017	21/04/2017	07/06/2017	14/06/2017	Please Select	02/06/2017					Y	Y				
Yes		13/09/2016	12/01/2017	12/01/2017	13/02/2017	13/01/2017	Please Select	13/01/2017										
Yes		04/04/2016	02/05/2017	18/04/2017	04/04/2017	13/06/2017	Please Select	13/06/2017										
No		20/02/2017	08/08/2017	01/08/2017	08/08/2017	09/08/2017	Please Select	09/08/2017										
Yes		21/04/2017	20/07/2017	04/07/2017	21/04/2017	22/07/2017	Please Select	04/09/2017										
No		09/06/2017	04/09/2017	04/09/2017			Please Select...											
Yes		26/01/2017	01/03/2017	01/03/2017	30/03/2017	30/03/2017	Please Select	30/03/2017										

No		15/02/2017	10/07/2017	29/06/2017	13/07/2017	13/07/2017	Please Select	17/07/2017										Y	
Yes		08/09/2017	07/09/2017	07/09/2017	08/09/2017	14/09/2017	Please Select	14/09/2017											
No		12/07/2017	03/08/2017	05/09/2017	07/09/2017	07/09/2017	Please Select	07/09/2017											

Reasons for delay correspond to:
Neither
Sponsor
Neither
NHS Provider
Sponsor
Sponsor
Sponsor
NHS Provider
Sponsor
Neither

Sponsor
Sponsor
Sponsor
Sponsor
Neither
Neither
Neither
Sponsor
Neither
Neither
Sponsor

Sponsor
Neither
Sponsor
Neither
Sponsor
Sponsor
NHS Provider
Sponsor
Neither
Sponsor
Neither
NHS Provider
Sponsor
Both

Sponsor
NHS Provider
NHS Provider
Both
Both
Sponsor
Both
Sponsor
Sponsor
Both
Neither

Sponsor
Sponsor
Sponsor
Both
Both

Sponsor
Sponsor
Sponsor
Sponsor
Sponsor
NHS Provider
Sponsor
Sponsor
Sponsor
Neither
Neither
Neither
NHS Provider
Both

Sponsor